Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | NPY1R | P25929 | 1/20 | 0.60 |
| ▸ | NPY2R | P49146 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451885 | 1.00 | ADORA2A (0.61) | ADORA2AADORA2BTSHRLMNAPMP22 | |
| SCHEMBL29387907 | 1.00 | ADORA2A (0.61) | ADORA2AADORA2BTSHRLMNAPMP22 | |
| SCHEMBL28758971 | 0.92 | ADORA2A (0.65) | ADORA2AADORA2BTSHRLMNAPMP22 | |
| SCHEMBL30208555 | 0.88 | ADORA2A (0.60) | ADORA2AADORA2BTSHRLMNAPMP22 | |
| SCHEMBL28409183 | 0.87 | SLC29A1 (0.67) | ADORA2AADORA2BSLC29A1 | |
| SCHEMBL15865951 | 0.86 | BMPR1B (0.68) | ADORA2AADORA2BSLC29A1 | |
| SCHEMBL3022531 | 0.86 | BMPR1B (0.68) | ADORA2AADORA2BSLC29A1 | |
| SCHEMBL28477260 | 0.86 | ADORA2A (0.67) | ADORA2AADORA2BTSHRLMNAPMP22 | |
| SCHEMBL24920112 | 0.86 | ADORA2A (0.67) | ADORA2AADORA2BTSHRLMNAPMP22 | |
| SCHEMBL30208521 | 0.86 | ADORA2A (0.67) | ADORA2AADORA2BTSHRLMNAPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3685 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20250345406-A1 | CHIMERIC PROTEINS IN AUTOIMMUNITY | SHATTUCK LABS INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250325494-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | THEMEDIUM THERAPEUTICS CO., LTD. (CN) | 2025-10-23 | — | — | US | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| US-20250188013-A1 | LIPID COMPOUND AND USE THEREOF | THEMEDIUM THERAPEUTICS CO., LTD. (CN) | 2025-06-12 | — | — | US | claimed |
| EP-4565692-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| EP-4554616-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2025-05-21 | — | — | EP | claimed |
| US-20250019719-A1 | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2025-01-16 | — | — | US | claimed |
| CN-117866948-B | Negative selection method and system for purifying circular nucleic acid | 上海环码生物医药有限公司 | 2024-12-13 | — | — | CN | claimed |
| EP-2710136-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF FOR NON-HUMAN VERTEBRATES | Moderna Therapeutics, Inc. (US) | 2014-03-26 | — | — | EP | claimed |
| EP-2691101-A2 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | Moderna Therapeutics, Inc. (US) | 2014-02-05 | — | — | EP | claimed |
| WO-2013151736-A2 | IN VIVO PRODUCTION OF PROTEINS | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | claimed |
| WO-2013151671-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF COSMETIC PROTEINS AND PEPTIDES | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | claimed |
| WO-2013151672-A2 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | claimed |
| WO-2013039857-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | modeRNA Therapeutics (US) | 2013-03-21 | — | — | WO | claimed |
| WO-2013039861-A2 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | modeRNA Therapeutics (US) | 2013-03-21 | — | — | WO | claimed |
| WO-2012158736-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF FOR NON-HUMAN VERTEBRATES | modeRNA Therapeutics (US) | 2012-11-22 | — | — | WO | claimed |
| US-20120251618-A1 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | modeRNA Therapeutics (US) | 2012-10-04 | — | — | US | claimed |
| WO-2012135805-A2 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | modeRNA Therapeutics (US) | 2012-10-04 | — | — | WO | claimed |